Pembrolizumab/Chemoradiotherapy Approval is ‘Huge Win’ in Cervical Cancer
January 12th 2024Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
2-Minute Drill: Closing Thoughts on the 2023 ASH Annual Meeting
January 12th 2024Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to share their closing thoughts before the 2-Minute Drill winner is announced.
Defining Success in Multiple Myeloma Induction and Maintenance
January 12th 2024Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.
Importance of Managing Nausea Related to T-DXd in HR+ Breast Cancer
January 7th 2024Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.